RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Dbv Technologies Stock

Dbv Technologies Stocks 2024

Dbv Technologies Stocks

95.12 M

Ticker

DBV.PA

ISIN

FR0010417345

WKN

A1JWB7

In 2024, Dbv Technologies had 95.12 M outstanding stocks, a 0% change from the 95.12 M stocks in the previous year.

The Dbv Technologies Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2029e95.12
2028e95.12
2027e95.12
2026e95.12
2025e95.12
2024e95.12
202395.12
202277.38
202154.92
202054.09
201937.01
201828.92
201724.76
201624.45
201521.52
201416.09
201312.33
201213.6
201113.4
201013.4

Dbv Technologies shares outstanding

The number of shares was Dbv Technologies in 2023 — This indicates how many shares 95.121 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Dbv Technologies earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Dbv Technologies's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Dbv Technologies’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Dbv Technologies's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Dbv Technologies Aktienanalyse

What does Dbv Technologies do?

DBV Technologies SA (DBV) is a biopharmaceutical company specializing in the development of therapies for allergic diseases. The company was founded in 2002 by Pierre-Henri Benhamou in France. Its objective is to set new standards in the treatment of allergies through innovative approaches. DBV's business model is based on the research and development of products based on epicutaneous tests (application of allergens on the skin). This alternative method to the common oral immunotherapy (OIT) treats allergic reactions using special patch products. These patches contain the allergens that trigger an allergic reaction in the patient. Through continuous contact with the allergens, the body's defense mechanisms learn that there is no threat and suppress the allergic reaction. DBV offers two products based on epicutaneous tests: Viaskin Peanut and Viaskin Milk. Viaskin Peanut is DBV's first product for the treatment of peanut allergies, while Viaskin Milk is the next product in the pipeline. Viaskin Peanut is a patch that contains a microdose of peanut protein. It is applied to the patient's skin, gradually familiarizing the immune system with the allergen and reducing allergic reactions. The patch can also be used in children, making it an important innovation in the treatment of peanut allergies. Viaskin Milk is also a patch that contains specific proteins found in milk. This patch aims to revolutionize the treatment of milk intolerances, as there are currently no specific therapies for this type of allergy. Again, this is an epicutaneous test. DBV has previously entered into several partnerships with other companies. This includes a collaboration with Nestle to further expand the potential of epicutaneous test products. Networking with insurers and health insurance companies is also an important strategic step in establishing the use of epicutaneous test products in practice. The company is particularly active in Europe and the USA. Its IPO took place in 2012. In 2017, DBV became the first French drug manufacturer to receive approval from the European Medicines Agency (EMA) for Viaskin Peanut. DBV Technologies SA has great potential in the development of epicutaneous products for long-term treatment of allergies. The company has achieved promising results in a short period of time and has established itself as an innovative player in the field of allergology. Dbv Technologies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Dbv Technologies's Shares Outstanding

Dbv Technologies's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Dbv Technologies’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Dbv Technologies’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Dbv Technologies’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Dbv Technologies stock

How many stocks are there of Dbv Technologies?

The current number of stocks of Dbv Technologies is 95.12 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Dbv Technologies are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Dbv Technologies evolved in recent years?

The number of shares of Dbv Technologies has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Dbv Technologies as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Dbv Technologies?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Dbv Technologies pay?

Over the past 12 months, Dbv Technologies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Dbv Technologies is expected to pay a dividend of 0 USD.

What is the dividend yield of Dbv Technologies?

The current dividend yield of Dbv Technologies is .

When does Dbv Technologies pay dividends?

Dbv Technologies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Dbv Technologies?

Dbv Technologies paid dividends every year for the past 0 years.

What is the dividend of Dbv Technologies?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Dbv Technologies located?

Dbv Technologies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Dbv Technologies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Dbv Technologies from 9/21/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/21/2024.

When did Dbv Technologies pay the last dividend?

The last dividend was paid out on 9/21/2024.

What was the dividend of Dbv Technologies in the year 2023?

In the year 2023, Dbv Technologies distributed 0 USD as dividends.

In which currency does Dbv Technologies pay out the dividend?

The dividends of Dbv Technologies are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Dbv Technologies stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Dbv Technologies

Our stock analysis for Dbv Technologies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dbv Technologies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.